Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
44.77 USD | -2.36% | -8.13% | +62.80% |
05-13 | Merus Says US FDA Grants Breakthrough Therapy Designation for Petosemtamab | MT |
05-13 | Merus Carcinoma Treatment Awarded US FDA's Breakthrough Therapy Designation | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+62.80% | 2.63B | |
+5.33% | 111B | |
+12.11% | 106B | |
-12.56% | 22.24B | |
-3.11% | 21.25B | |
-5.89% | 18.97B | |
-35.21% | 18.52B | |
-10.86% | 16.81B | |
+37.57% | 12.54B | |
-26.24% | 8.09B |
- Stock Market
- Equities
- MRUS Stock
- News Merus N.V.
- Citigroup Adjusts Price Target on Merus to $47 From $38, Maintains Buy Rating